The current research aimed to increase patient adherence, bioavailability, and medication release by developing and evaluating Alfuzosin HCI extended-release tablets. Ethyl Cellulose, Carbopol 940, and HPMC K4 were among the polymers used in the direct compression technique to develop a range of compositions. All pre-compression metrics, including bulk density, tapped density, angle of repose, Carr's index, and Hausner's ratio, were found to be within acceptable ranges in the manufactured tablets, indicating that the flow properties were satisfactory. The tablets that were crushed were tested for additional characteristics after compression, such as hardness, thickness, weight fluctuation, friability, drug content, and in vitro drug release. Again, they were determined to be satisfactory. F6, which contains Carbopol 940, showed the best results among all the formulations. It had an extended-release profile, releasing 99.83% of the medication over 12 hrs. The evaluation criteria revealed that formulation F6 was the most promising candidate for the treatment of benign prostatic hyperplasia with its extended-release dosage form.